Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC; KIDCARE Multicenter Study Group; Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S. Roberts SC, et al. Among authors: simonsen k. Contemp Clin Trials. 2019 Apr;79:98-103. doi: 10.1016/j.cct.2019.02.008. Epub 2019 Mar 3. Contemp Clin Trials. 2019. PMID: 30840903 Free article.
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S; KIDCARE Multicenter Study Group. Burns JC, et al. Lancet Child Adolesc Health. 2021 Dec;5(12):852-861. doi: 10.1016/S2352-4642(21)00270-4. Epub 2021 Oct 27. Lancet Child Adolesc Health. 2021. PMID: 34715057 Free article. Clinical Trial.
Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United States.
Burney JA, Roberts SC, DeHaan LL, Shimizu C, Bainto EV, Newburger JW, Dominguez S, Jone PN, Jaggi P, Szmuszkovicz JR, Rowley AH, Samuy N, Scalici P, Tremoulet AH, Cayan DR, Burns JC; KIDCARE Study Investigators. Burney JA, et al. JAMA Netw Open. 2022 Jun 1;5(6):e2217436. doi: 10.1001/jamanetworkopen.2022.17436. JAMA Netw Open. 2022. PMID: 35713905 Free PMC article.
Recurrent midline frontal mass in a patient with sinusitis.
Patel SA, Chatterjee A, Simonsen K. Patel SA, et al. Among authors: simonsen k. Clin Pediatr (Phila). 2011 Mar;50(3):266-8. doi: 10.1177/0009922809352680. Epub 2010 Jan 28. Clin Pediatr (Phila). 2011. PMID: 20118095 No abstract available.
Powassan encephalitis and Colorado tick fever.
Romero JR, Simonsen KA. Romero JR, et al. Infect Dis Clin North Am. 2008 Sep;22(3):545-59, x. doi: 10.1016/j.idc.2008.03.001. Infect Dis Clin North Am. 2008. PMID: 18755390 Review.
Valganciclovir for symptomatic congenital cytomegalovirus disease.
Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Kimberlin DW, et al. Among authors: simonsen k. N Engl J Med. 2015 Mar 5;372(10):933-43. doi: 10.1056/NEJMoa1404599. N Engl J Med. 2015. PMID: 25738669 Free PMC article. Clinical Trial.
Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents.
Gonzalez D, James LP, Al-Uzri A, Bosheva M, Adler-Shohet FC, Mendley SR, Bradley JS, Espinosa C, Tsonkova E, Moffett K, Marquez L, Simonsen KA, Stoilov S, Boakye-Agyeman F, Jasion T, Hornik CP, Hernandez R, Benjamin DK Jr, Cohen-Wolkowiez M. Gonzalez D, et al. Among authors: simonsen ka. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00692-18. doi: 10.1128/AAC.00692-18. Print 2018 Aug. Antimicrob Agents Chemother. 2018. PMID: 29891609 Free PMC article. Clinical Trial.
232 results